GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000974341 | Stomach | WIM | response to carbohydrate | 18/426 | 253/18723 | 2.12e-05 | 8.33e-04 | 18 |
GO:00346124 | Stomach | WIM | response to tumor necrosis factor | 18/426 | 253/18723 | 2.12e-05 | 8.33e-04 | 18 |
GO:00192211 | Stomach | WIM | cytokine-mediated signaling pathway | 26/426 | 472/18723 | 3.31e-05 | 1.16e-03 | 26 |
GO:000974641 | Stomach | WIM | response to hexose | 16/426 | 219/18723 | 4.40e-05 | 1.38e-03 | 16 |
GO:00971914 | Stomach | WIM | extrinsic apoptotic signaling pathway | 16/426 | 219/18723 | 4.40e-05 | 1.38e-03 | 16 |
GO:00332094 | Stomach | WIM | tumor necrosis factor-mediated signaling pathway | 10/426 | 99/18723 | 8.58e-05 | 2.40e-03 | 10 |
GO:0051146 | Stomach | WIM | striated muscle cell differentiation | 14/426 | 283/18723 | 5.58e-03 | 4.78e-02 | 14 |
GO:00316675 | Stomach | SIM | response to nutrient levels | 40/708 | 474/18723 | 1.97e-06 | 1.02e-04 | 40 |
GO:00713565 | Stomach | SIM | cellular response to tumor necrosis factor | 25/708 | 229/18723 | 2.06e-06 | 1.05e-04 | 25 |
GO:00346125 | Stomach | SIM | response to tumor necrosis factor | 26/708 | 253/18723 | 4.00e-06 | 1.70e-04 | 26 |
GO:000974351 | Stomach | SIM | response to carbohydrate | 25/708 | 253/18723 | 1.21e-05 | 4.30e-04 | 25 |
GO:003428451 | Stomach | SIM | response to monosaccharide | 23/708 | 225/18723 | 1.55e-05 | 5.19e-04 | 23 |
GO:000974651 | Stomach | SIM | response to hexose | 22/708 | 219/18723 | 3.09e-05 | 9.18e-04 | 22 |
GO:00971915 | Stomach | SIM | extrinsic apoptotic signaling pathway | 22/708 | 219/18723 | 3.09e-05 | 9.18e-04 | 22 |
GO:00332095 | Stomach | SIM | tumor necrosis factor-mediated signaling pathway | 13/708 | 99/18723 | 8.97e-05 | 2.25e-03 | 13 |
GO:00097501 | Stomach | SIM | response to fructose | 4/708 | 10/18723 | 3.55e-04 | 6.34e-03 | 4 |
GO:000188941 | Stomach | SIM | liver development | 15/708 | 147/18723 | 4.62e-04 | 7.65e-03 | 15 |
GO:006100841 | Stomach | SIM | hepaticobiliary system development | 15/708 | 150/18723 | 5.73e-04 | 8.78e-03 | 15 |
GO:00192212 | Stomach | SIM | cytokine-mediated signaling pathway | 32/708 | 472/18723 | 1.10e-03 | 1.43e-02 | 32 |
GO:003103231 | Stomach | SIM | actomyosin structure organization | 17/708 | 196/18723 | 1.28e-03 | 1.59e-02 | 17 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KRT1 | SNV | Missense_Mutation | novel | c.62C>T | p.Ser21Phe | p.S21F | P04264 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
KRT1 | SNV | Missense_Mutation | novel | c.1807N>A | p.Gly603Ser | p.G603S | P04264 | protein_coding | tolerated_low_confidence(0.56) | benign(0.006) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
KRT1 | SNV | Missense_Mutation | rs771587972 | c.751N>T | p.Arg251Trp | p.R251W | P04264 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KRT1 | SNV | Missense_Mutation | | c.1027N>T | p.Arg343Cys | p.R343C | P04264 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
KRT1 | SNV | Missense_Mutation | | c.1307C>T | p.Ala436Val | p.A436V | P04264 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B6-A0IC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KRT1 | deletion | Frame_Shift_Del | novel | c.402delN | p.Phe134LeufsTer43 | p.F134Lfs*43 | P04264 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
KRT1 | SNV | Missense_Mutation | | c.655N>A | p.Asp219Asn | p.D219N | P04264 | protein_coding | tolerated(0.38) | benign(0.066) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
KRT1 | SNV | Missense_Mutation | | c.811N>C | p.Glu271Gln | p.E271Q | P04264 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
KRT1 | SNV | Missense_Mutation | novel | c.1811C>T | p.Ser604Phe | p.S604F | P04264 | protein_coding | tolerated_low_confidence(0.09) | possibly_damaging(0.554) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
KRT1 | SNV | Missense_Mutation | novel | c.971N>G | p.Ser324Cys | p.S324C | P04264 | protein_coding | deleterious(0.02) | probably_damaging(0.923) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |